Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
DBS Survey Finds 78% of Businesses Diversify Settlement Currencies

DBS Survey Finds 78% of Businesses Diversify Settlement Currencies

BitgetBitget2026/11/03 05:39
  • DBS' Nov. 2, 2026, report found 78% of businesses diversified settlement currencies as shifting trade routes complicated cross-border operations.
  • Tokenised money adoption reached 88% through deployments or pilots; stablecoins were the most widely adopted instruments at 63%.
  • In Hong Kong, 81% used renminbi for alternative settlement; 67% identified limited real-time cash visibility as the leading diversification-related liquidity challenge.
  • Around three-quarters of respondents reported or expected AI-driven improvements in treasury management and payment processing within two years.
  • Banks faced demand for tokenised money integration from 64% of respondents; 63% sought support for pilots, proofs of concept and integration.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DBS Group Holdings Ltd. published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12